These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23709704)

  • 1. Novel methodologic approaches to phase I, II, and III trials.
    Yeatts SD
    Stroke; 2013 Jun; 44(6 Suppl 1):S116-8. PubMed ID: 23709704
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel endpoints and design of early clinical trials.
    Parulekar WR; Eisenhauer EA
    Ann Oncol; 2002; 13 Suppl 4():139-43. PubMed ID: 12401680
    [No Abstract]   [Full Text] [Related]  

  • 3. Applying a phase II futility study design to therapeutic stroke trials.
    Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
    Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
    Ghimire S; Kyung E; Kim E
    Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of pharmacoepidemiology.
    Wertheimer AL; Andrews KB
    Pharm World Sci; 1995 May; 17(3):61-6. PubMed ID: 7550051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
    Gentzler RD; Yentz SE; Johnson ML; Rademaker AW; Patel JD
    Cancer; 2014 Dec; 120(24):3853-8. PubMed ID: 25155290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial watch: phase II and phase III attrition rates 2011-2012.
    Arrowsmith J; Miller P
    Nat Rev Drug Discov; 2013 Aug; 12(8):569. PubMed ID: 23903212
    [No Abstract]   [Full Text] [Related]  

  • 9. Point: Intraperitoneal chemotherapy in the management of ovarian cancer.
    Markman M
    J Natl Compr Canc Netw; 2004 Nov; 2(6):549-54. PubMed ID: 19780298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Women in early-phase clinical drug trials: have things changed over the past 20 years?
    Fleisch J; Fleisch MC; Thürmann PA
    Clin Pharmacol Ther; 2005 Nov; 78(5):445-52. PubMed ID: 16321610
    [No Abstract]   [Full Text] [Related]  

  • 11. Reinventing clinical trials.
    Allison M
    Nat Biotechnol; 2012 Jan; 30(1):41-9. PubMed ID: 22231093
    [No Abstract]   [Full Text] [Related]  

  • 12. Preclinical phase III trials in translational stroke research: call for collective design of framework and guidelines.
    Boltze J; Ayata C; Wagner DC; Plesnila N
    Stroke; 2014 Feb; 45(2):357. PubMed ID: 24407954
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of clinical research beyond phase III trials.
    Vogelbaum MA
    Clin Neurosurg; 2009; 56():37-9. PubMed ID: 20214028
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trial opportunities in hemostasis and thrombosis: NHBLI State-of-the-Science symposium.
    Cines DB; Blajchman MA; High KA; Bussel JB;
    Am J Hematol; 2012 Feb; 87(2):235-8. PubMed ID: 22120890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.
    Lang FF; Gilbert MR; Puduvalli VK; Weinberg J; Levin VA; Yung WK; Sawaya R; Fuller GN; Conrad CA
    Neuro Oncol; 2002 Oct; 4(4):268-77. PubMed ID: 12356357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomics drugs in clinical trials.
    Hall J; Dennler P; Haller S; Pratsinis A; Säuberli K; Towbin H; Walther K; Woytschak J
    Nat Rev Drug Discov; 2010 Dec; 9(12):988. PubMed ID: 21119735
    [No Abstract]   [Full Text] [Related]  

  • 18. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
    Davies G; Boeree M; Hermann D; Hoelscher M
    PLoS Med; 2019 Jul; 16(7):e1002851. PubMed ID: 31287813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.